Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences
August 9, 2023
Ocular Therapeutix™ to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
August 7, 2023
Ocular Therapeutix™ Provides Second Quarter 2023 Financial Results and Corporate Update
July 24, 2023
Ocular Therapeutix™ To Report Second Quarter 2023 Financial Results
July 12, 2023
Ocular Therapeutix™ Announces Appointment of New Board Member
June 10, 2023
Ocular Therapeutix™ Announces 12-Month Topline Data from Ongoing U.S.-Based Phase 1 Clinical Trial Evaluating OTX-TKI for Treatment of Wet AMD
June 7, 2023
Ocular Therapeutix™ Completes Enrollment of the HELIOS Clinical Trial of OTX-TKI for the Treatment of Diabetic Retinopathy
June 5, 2023
Ocular Therapeutix™ To Present 12-Month Top-Line Data from U.S.-Based Phase 1 Clinical Trial of OTX-TKI in Wet Age-Related Macular Degeneration at the 2023 Clinical Trials at the Summit Annual Meeting
June 1, 2023
Ocular Therapeutix™ to Present at the Jefferies Global Healthcare Conference
May 8, 2023
Ocular Therapeutix™ Provides First Quarter 2023 Financial Results and Corporate Update
May 8, 2023
Ocular Therapeutix™ to Present at the JMP Securities Life Sciences Conference
April 28, 2023
Ocular Therapeutix™ To Present Data at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
April 24, 2023
Ocular Therapeutix™ To Report First Quarter 2023 Financial Results
April 14, 2023
Ocular Therapeutix™ To Present Pre-Clinical and Clinical Data at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
March 6, 2023
Ocular Therapeutix™ Provides Fourth Quarter and Year-End 2022 Results and Corporate Update
February 28, 2023
Ocular Therapeutix™ to Present at Cowen’s 43rd Annual Healthcare Conference
February 21, 2023
Ocular Therapeutix™ To Report Fourth Quarter and Year-End 2022 Financial Results
February 11, 2023
Ocular Therapeutix™ Announces Interim 10-month Data from the Ongoing U.S. Phase 1 Clinical Trial Evaluating OTX-TKI for the Treatment of Wet AMD
January 6, 2023
Ocular Therapeutix™ Provides 2022 Year End Corporate Update and Reviews Expected 2023 Milestones
